[68Ga]Ga-FAPI在胰腺腺鳞癌再分期中优于[18F]FDG
本文报告一例33岁女性胰腺腺鳞癌(PASC)患者,基线[18F]FDG PET/CT完成IV期分期,FOLFIRINOX化疗后代谢完全缓解,但5个月内复发。再分期时[18F]FDG PET/CT未显示高代谢病灶,而[68Ga]Ga-FAPI PET/CT成功识别局部和转移性复发。
要点
- PASC侵袭性强、生存期有限,需精准再分期。
- FOLFIRINOX后代谢完全缓解仍可5个月内复发。
- 复发再分期中[68Ga]Ga-FAPI PET/CT优于[18F]FDG PET/CT。
核心结论
- 本病例提示[68Ga]Ga-FAPI PET/CT在检测复发性胰腺腺鳞癌方面优于[18F]FDG PET/CT。
研究设计与样本
- 本文为个案报告,描述一例33岁女性胰腺腺鳞癌患者的诊治与影像随访过程。
主要发现
- 基线[18F]FDG PET/CT完成IV期恶性肿瘤的准确分期和治疗计划。
- FOLFIRINOX化疗后随访[18F]FDG PET/CT显示代谢完全缓解。
- 代谢完全缓解后5个月内疾病复发。
- 再分期时[18F]FDG PET/CT未显示任何高代谢病灶。
- 再分期时[68Ga]Ga-FAPI PET/CT成功识别局部和转移性复发。
临床怎么用
- 对胰腺腺鳞癌复发再分期,可考虑[68Ga]Ga-FAPI PET/CT以弥补[18F]FDG PET/CT阴性结果。
局限性
- 本文为单例个案报告,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pancreatic adenosquamous carcinoma (PASC) represents a rare, aggressive exocrine neoplasm. We describe a 33-year-old woman with an aggressive disease trajectory and limited survival. Baseline [18F]FDG PET/CT enabled accurate staging and treatment planning of stage IV malignancy. Following FOLFIRINOX chemotherapy, complete metabolic resolution was achieved on follow-up [18F]FDG PET/CT. Nevertheless, disease relapse ensued within 5 months. During restaging, [18F]FDG PET/CT failed to reveal any hypermetabolic lesions, whereas [68Ga]Ga-FAPI PET/CT successfully identified both local and metastatic recurrences. Notably, this case highlights the superiority of [68Ga]Ga-FAPI PET/CT for detecting recurrent PASC compared with [18F]FDG PET/CT.
引用
- Abdlkadir AS, Haddad H, Mohamad I, et al. [68Ga]Ga-FAPI Surpasses [18F]FDG in Pancreatic Adenosquamous Carcinoma Restaging. Clin Nucl Med. 2026. PMID: 41632577. doi:10.1097/RLU.0000000000006284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。